PPCB

Today, 8:35 AMPropanc Biopharma reports new preclinical PRP data in pancreatic cancer and files Australian patent on galunisertib combination

Peers: PMCB SLXN NCNA PCSA RNXT ONCY ELTX IMMP KZIA ATHE

Scroll to Statements

Index	-
Market Cap	2.00M
Enterprise Value	1.68M
Income	-19.79M
Sales	0.00M
Book/sh	28.40
Cash/sh	0.80
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Nov 12, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.07
P/C	2.41
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.55
Current Ratio	2.55
Debt/Eq	0.05
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-258.08
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	98.13% 97.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.74%
Sales Y/Y TTM	-
EPS Q/Q	84.24%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	0.46%
Inst Trans	-
ROA	-116.39%
ROE	-161.86%
ROIC	-200.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-41.58%
SMA50	-70.42%
SMA200	-91.59%
Trades

Shs Outstand	0.33M
Shs Float	-
Short Float	-
Short Ratio	0.03
Short Interest	0.01M
52W High	319.88 -99.39%
52W Low	1.79 8.14%
Volatility	18.40% 12.62%
ATR (14)	0.57
RSI (14)	23.03
Beta	3.35
Rel Volume	0.33
Avg Volume	186.37K
Volume	3,049

Perf Week	-15.47%
Perf Month	-61.86%
Perf Quarter	-81.02%
Perf Half Y	-92.48%
Perf YTD	-98.56%
Perf Year	-99.38%
Perf 3Y	-100.00%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	-
Target Price	380.00
Prev Close	1.84
Price	1.94
Change %	5.20%

Today 08:30AM	Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-ß Inhibitor on TGF-ß Pathway in Pancreatic Cancer (GlobeNewswire) +5.20%
Oct-30-26 08:30AM	Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients (GlobeNewswire) -12.80%
Oct-28-26 08:30AM	Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients (GlobeNewswire) -13.17%
Oct-26-26 08:30AM	Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability (GlobeNewswire) -18.21%
Oct-22-26 04:24PM	CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans (GlobeNewswire) -13.13%
08:30AM	Loading…
08:30AM	Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans (GlobeNewswire)
Oct-16-26 08:36AM	Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells (GlobeNewswire)
Oct-14-26 08:30AM	Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer (GlobeNewswire) -11.35%
Oct-07-26 08:30AM	Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib (GlobeNewswire)
Sep-29-26 08:30AM	Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results (GlobeNewswire)
Sep-22-26 08:30AM	Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 (GlobeNewswire)
Sep-16-26 08:30AM	Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. (GlobeNewswire) -22.56%
Sep-09-26 08:30AM	Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 (GlobeNewswire)
Aug-27-26 10:29AM	Propanc Biopharma Reports PRP Preclinical Pancreatic Cancer Data Showing Over 90% Tumor Growth Inhibition (InvestorsHub) +108.41%
08:30AM	Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit (GlobeNewswire)
08:30AM	Loading…
Aug-18-26 08:30AM	Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP (GlobeNewswire)
Aug-12-26 08:30AM	Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers (GlobeNewswire)
Aug-06-26 08:30AM	Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models (GlobeNewswire) +15.25%
Aug-05-26 08:30AM	Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program (GlobeNewswire) +15.69%
Jul-21-26 08:30AM	Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal (GlobeNewswire)
Jul-07-26 08:30AM	Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd (GlobeNewswire)
Jul-02-26 08:30AM	Propanc Biopharma Initiates $5.0 Million Share Repurchase Program (GlobeNewswire) +22.92%
Jun-16-26 08:45AM	Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study (GlobeNewswire) -10.23%
Jun-11-26 12:37PM	PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split Whats Driving Todays Smashing Rally? (Stocktwits) +80.00%
08:30AM	Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program (GlobeNewswire)
Jun-02-26 05:30AM	Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain (GlobeNewswire)
May-20-26 08:45AM	Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade (GlobeNewswire) -12.22%
May-19-26 08:45AM	Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 - 40 Advanced Cancer Patients (GlobeNewswire)
May-15-26 08:45AM	Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results (GlobeNewswire) -6.98%
May-13-26 10:00PM	Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans (GlobeNewswire) -21.40%
10:30AM	Loading…
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +13.44%
Mar-24-26 08:45AM	Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaen and Granada, Spain (GlobeNewswire) -5.94%
Mar-12-26 08:45AM	Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy (GlobeNewswire) -13.57%
Mar-10-26 08:45AM	Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study (GlobeNewswire) -20.47%
Mar-03-26 08:45AM	Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models (GlobeNewswire) -5.16%
Feb-18-26 08:45AM	Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results (GlobeNewswire)
Feb-05-26 08:45AM	Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market (GlobeNewswire) +5.71%
Jan-27-26 08:45AM	Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations (GlobeNewswire) +6.52%
Jan-20-26 08:45AM	Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia (GlobeNewswire)
Jan-15-26 08:45AM	Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer (GlobeNewswire) -17.13%
Jan-13-26 08:45AM	Propanc Biopharma Provides Shareholder Update (GlobeNewswire)
Dec-22-25 07:00AM	Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal (GlobeNewswire) -8.45%
Dec-04-25 08:45AM	Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs (GlobeNewswire)
Dec-01-25 08:45AM	Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis (GlobeNewswire) +5.47%
Nov-17-25 08:45AM	Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results (GlobeNewswire)
Nov-10-25 08:45AM	Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline (GlobeNewswire) -12.43%
Nov-04-25 07:00AM	Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) (GlobeNewswire) -6.19%
Oct-15-25 05:45PM	CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital (GlobeNewswire) -8.67%
08:45AM	Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital (GlobeNewswire)
Oct-07-25 08:45AM	Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy (GlobeNewswire)
Sep-17-25 08:45AM	Propanc Biopharma Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office (GlobeNewswire)
Sep-02-25 09:00AM	Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum (GlobeNewswire) -9.60%
Aug-25-25 07:30AM	Propanc Biopharma Provides Shareholder Update (GlobeNewswire)
Aug-19-25 08:30AM	Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ (GlobeNewswire) -37.26%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +103.83%
Aug-14-25 11:00PM	Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering (GlobeNewswire) +30.00% -72.40%

Show Previous News

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

CEO & Executive ChairmanMr. James Nathanielsz

Chief Financial OfficerMs. Jeannine Zimmerman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Propanc Biopharma Inc

Upgrade your Finviz experience